Terns Pharmaceuticals Announces Publication Of TERN-701 Trial-In-Progress Abstract For 2023 ASCO Meeting
Portfolio Pulse from Benzinga Newsdesk
Terns Pharmaceuticals announced the publication of a trial-in-progress abstract for TERN-701, an allosteric BCR-ABL, for the 2023 ASCO Meeting. The China Phase 1 trial has completed enrollment of Cohort 5 in the Dose Escalation phase.
May 25, 2023 | 9:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Terns Pharmaceuticals' TERN-701 trial progresses with the completion of Cohort 5 enrollment in the China Phase 1 trial.
The publication of the trial-in-progress abstract for TERN-701 and the completion of Cohort 5 enrollment in the China Phase 1 trial indicate progress in Terns Pharmaceuticals' drug development. This positive news may lead to a short-term increase in the stock price of TERN.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100